Eastwoods Consulting
Notes from the East Woods

musings on opportunities in the life science marketplace 

  May 2012      
  
EC border

Greetings!

The optimism of a great day of fishing can help us think rationally about the outlook for our new products.  Please have a read and feel free to let me know what you think. 



Regards,

Paul Danis
Founder and Principal

Join Our Mailing List!
This Month's Features
- High Hopes, Empty Creel
- Life Science Market Update
- About Eastwoods Consulting
High Hopes, Empty Creel

 

 I had nothing to show for my 3 recent mornings of fishing on the local ponds and lakes. I had started with great hopes of catching a keeper, especially after reading that a third of the state record fish came out of the big lake at the end of the road. However, I was skunked, much like the new product launched with great fanfare and hope, but languishing unloved upon the shelf.

 

So what causes us to so grandly and totally misjudge the outlook for our efforts? I think the root lies in our culture of working in a technical field with inherent risks. Because of this we have all become tremendous optimists to buffer ourselves against the failures. This is not necessarily a bad thing since it helps us envision new opportunities where none had existed. But it also blinds us to the reality that the future is not always rosy, and sometimes our ideas just not that good.

 

To help steer our way out of this tendency to forecast hockey sticks and exponential growth, here are a few suggestions.

  • First acknowledge that not all ideas and product concepts should be commercialized. Some are best left as notes on a napkin. The poster child for this is Pfizer's excursion into inhaled insulin with Exubera. After $12M in sales of the supposed blockbuster, they pulled the plug and wrote down $2.8B.
  • Develop a framework for rapidly assessing whether a concept has legs in the marketplace. There are a lot of good approaches for doing this so pick one and stick to it.
  • Casting your bait into the lake at mid-day is unlikely to rouse the wily lake trout that is resting on the bottom. Ultimately your market (aka customers) has to be sitting there with an open mouth, awaiting something to satisfy its hunger. They need to have a big problem, gap, need, or whatever you want to call it.
  • Looking around the shore I saw a few other fishermen, and it appeared that they also had empty creels. Having other competitive products in the market is not adequate validation that you should too. They aren't necessarily smarter or cleverer than you.
  • Lastly if you go home unlucky or with only 30% of your forecast, be sure to learn as much as you can - why did some buy (or bite) and others not. How satisfied are the customers, and how did the competitors react? As the Pfizer CEO said, "We will, of course, evaluate closely what happened here." On my way home from the lake, I thought about all the factors that lead to my lack of success - bait, time of day, weather, lunar cycle, etc.

So when you are looking to the future of your next great product, be sure to use a disciplined view and don't become blinded by the optimism of a great day of hunting keepers. That said, I'm still thinking that my next day on the lake may bring in that four-pounder...

 

 


Life Science Market Update

Index

Apr. Value

Change 12mo.

12 mo. High

12 mo. Low

EC BioTools

620

-13%

722

532

EC BigPharma

953

6%

953

821

EC Biotech

810

11%

810

624



The Tools sector was down a few percent for the month, led by Illumina's decline of 15% after Roche's failed takeover bid.  Both BigPharma and Biotech posted 12 month highs, BigPharma moving up 2%, while Biotech was up 5%. In BigPharma, most stocks wagged a few percent up or down, while Biotech was its usual volatile self with HGS up 79% and Intermune down 29%. Intermune was downgraded due to a delay in its clinical trial for its lung disease drug, Esbriet. HGS is soaring on news of GSK's $2.6 billion unsolicited bid to buy it.

 

 
EC BioIndex
May2012





---------------------
Many of the life science indices currently available are a mixture of various types of companies. In order to better assess the situation in the different segments, Eastwoods Consulting has created these price-weighted indices for the sectors of large pharmaceutical companies, biotech companies, and life science research tools companies.
  •   EC BioTools Index - A, ACCL, AFFX, BIO, BRKR, HBIO, ILMN, LIFE, LMNX, PKI, QGEN, SIAL, TECH, TMO, WAT
  •   EC BigPharma Index - JNJ, PFE, GSK, NVS, SNY, LUN, ABT, LLY, AZN, WYE, BMY, NVO, BAX, TEVA, VRX.TO, ROG.VX
  •   EB Biotech Index - ALKS, AMGN, AMLN, BIIB,BMRN, CPHD, DNDN, GILD, HGSI, IDXX, ITMN, NKTR, PDLI, REGN, SGMO, SHPGY, THRX, VRTX  
  •   Prices are taken at the close of each month.   
EC Border
 
About Eastwoods Consulting
Eastwoods Consulting

Translating Innovations into Profits for the Life Science Industrysm

Eastwoods Consulting helps life science companies grow their businesses.  Please visit our web site or contact us to learn more about how we help companies succeed in competitive markets.
 


Copyright © 2012, Eastwoods Consulting. This publication may be freely redistributed in full or in part as long as full attribution including our contact information and web address, are included.  Eastwoods is a registered servicemark of Eastwoods Consultng.